Hadassah Medical School
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hadassah Medical School
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
AstraZeneca’s Ajay Gautam On Innovation From Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
AstraZeneca Head of Emerging Market Collaborations Ajay Gautam talks to PharmAsia News about the company’s R&D strategy and deals with local partners.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.